News

Public · Published

Guggenheim maintains Spyre Therapeutics at Buy, raises price target to $135 from $130

Guggenheim kept its Buy rating on Spyre Therapeutics and raised its price target to $135 from $130. The new target is 3.8% higher than the prior target and implies 36.0% upside from the November 3 closing price of $99.27.

Published:

Updated:

What happened

Guggenheim kept its Buy rating on Spyre Therapeutics and raised its price target to $135 from $130. The new target is 3.8% higher than the prior target and implies 36.0% upside from the November 3 closing price of $99.27.

Confirmed

Global impact / market context

A higher target signals that Guggenheim sees more potential value in Spyre shares, which could influence how investors weigh the company’s prospects. However, the target is an analyst estimate, not a guaranteed share price, and the article gives no new company operating or financial results.

Analyst inference

The recent analyst targets cited range from $120 to $121, while Guggenheim’s new $135 target is higher. That difference reflects varied analyst views rather than a change in Spyre’s reported business performance, which the article does not discuss.

Confirmed

What to watch

  1. Watch for later analyst rating or target changes; a target is an estimate, and shifts could alter investor expectations even without new company results. Analyst inference
  2. Compare future targets with Spyre Therapeutics’ share price and reported business updates to see whether analysts’ expectations are supported by company developments. Analyst inference
  3. The article reports recent targets ranging from $120 to $121, compared with Guggenheim’s $135 target, showing a difference among the published analyst estimates. Confirmed

Evidence

  • Original source link unavailable